Preparaty fuzidovoy kislotyv n aruzhnoy terapii atopicheskogodermatita



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Keywords

About the authors

O G Elisyutina

E S Fedenko

References

  1. Гущин И.С. Эпидермальный барьер и аллергия. Рос. Аллергол. Журн. 2007, № 2, с. 3-16.
  2. Кожные и венерические болезни: Руководство для врачей. Под ред. Ю.К. Скрипкина, В.Н. Мордовцева: В 2 т. - 2-е изд., перераб., доп. М., «Медицина». 1999, т. 1, 67с.
  3. Aly R. Microflora of atopic dermatitis. Arch. Dermatol. 1977, v. 113, p. 780-782.
  4. Bunikowski R., Mielke M.E., Skarabis H., Worm M. et al. Evidence for a disease promoting effect of Staphylococcus aureus derived exotoxins in atopic dermatitis. J. Allergy Clin. Immunol. 2000, v. 105(4), p. 814-819.
  5. Breuer K., Kapp A., Werfel T. Bacterial infections and atopic dermatitis. Allergy. 2001, v. 56, p.1034-1041
  6. Leung D.Y.M. Role of Staphylococcus aureus in atopic dermatitis. Atopic dermatitis edited by T.Bieber, D.Y. M. Leung, Marcel-Dekker, Inc. New-York-Basil. 2002, p. 401-418.
  7. Смирнова Г.И. Современные подходы к лечению, ре- абилитации атопического дерматита, осложненного вторичной инфекцией. Аллергология и иммунология в педиатрии. 2004, № 1, с. 34-39.
  8. Современная наружная терапия дерматозов. Под ред. Н.Г. Короткого. Тверь, Губернская медицина. 2001, 5-10, с. 85-99.
  9. Белькова Ю.А. Фузидовая кислота в современной кли- нической практике. Клин. микробиол. и антимикробная химиотерапия. 2001. - Т. 3, № 4, стр. 324-338.
  10. Bendtzen K., Diamant M., Faber V. Fusidic acid, an immunosupressive drug with functions similar to cyclosporin A. Cytokine. 1990, v. 2, p. 423-429.
  11. Leyden J.J., Marples R.R., Kligman A.M. Staphylococcus aureus in the lesions of atopic dermatitis. Br. J. Dermatol. 1974, v. 90, p. 525-530.
  12. Wachs G.N., Maibach H.I. Co-operative double-blind trial of an antibiotic/corticoid combination in impetiginized atopic dermatitis. Br. J. Dermatol. 1976, v. 95, p. 323-328
  13. Hjorth N., Schmidt H., Thomsen K. Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmatherapeutica. 1985, v. 4, p. 126-131.
  14. Ramsay C.A., Savoie J.M., Gilbert M. et al. The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. J. Eur. Acad. Dermatol. Venereol. 1996, v. 7 (suppl 1), p. 15-22.
  15. Javier P.R., Ortiz M., Torralba M. et al. Fusidic acid/betamethasone in infected dermatoses - a double-blind comparison with neomycin/betamethasone. Br. J. Clin. Prac. 1986, v. 40, p. 235-238.
  16. Strategos J. Fusidic acid-betamethasone combination in infected eczema: an open, randomized comparison with gentamicin-betamethasone combination. Pharmatherapeutica. 1986, v. 4, p. 601-606.
  17. Ravenscroft J.C., Layton A.M., Eady E.A. et al. Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant (FusR) Staphylococcus aureus in atopic eczema. Br. J. Derm. 2003, v. 148, p. 1010-1017.
  18. Filius P.M., Gyssens I.C. Impact of increasing antimicrobial resistance on wound management. Am. J. Clin. Dermatol. 2002, v. 3, p. 1-7.
  19. Jones M.E., Karlowsky J.A., Draghi D.C. et al. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: A guide to appropriate antimicrobial therapy. Int. J. Antimicrob. Agents. 2003, v. 22, p. 406-419.
  20. Korting H.C., Neubert U., Abeck D. Current antimicrobial susceptibility of cutaneous bacteria to first line antibiotics. Int. J. Antimicrob. Agents. 1998, v. 10, p. 165-168.
  21. Hoeger P.H. Antimicrobial susceptibility of skin-colonization S. aureus strains in children with atopic dermatitis. Pediatr. Allergy Immunol. 2004, v. 15, p. 474-477.
  22. Osterlund A., Eden T., Olsson-Liljequist B. et al. Clonal spread among Swedish children of Staphylococcus aureus resistant to fusidic acid. Scand. J. Inf. Dis. 2002, v. 34, p. 729-734.
  23. Livermore D, James D, Duckworth G, Stephens P. Fusidic acid use and resistance. Lancet. 2002, v. 360, p. 806.
  24. Mason B.W.., Howard A.J., Magee J.T. Fusidic acid resistance in community isolates of methicillin-susceptible Staphylococcus aureus and fusidic acid prescribing. J. Antimicrob Chemother. 2003, v. 51, p. 1033-1036.
  25. Schultz Larsen F., Hanifin J.M. Epidemiology of atopic dermatitis. Immunol. All. Clin. North America. 2002, v. 22, p. 1-24.
  26. Shah M., Mohanraj M. High levels of fusidic acid-resistant Staphylococcus aureus in dermatology patients. Br. J. Derm. 2003, v. 148, 1018-1020.
  27. Sule O., Brown N.M., Willocks L.G. et al. Fusidic acid-resistant Staphylococcus aureus (FRSA) carriage in patients with atopic eczema and pattern of prior topical fusidic acid use. Int. J. Antimicrob. Agents. 2007, Jul., v. 30 (1), p. 78-82.
  28. Rennie R.P. Susceptibility of Staphylococcus aureus to fusidic acid: Canadian data. J. Cutan. Med. Surg. 2006, Nov-Dec., v. 10 (6), p. 277-280.
  29. Сидоренко С.В., Резван С.П., Грудинина С.А. и соавт. Результаты многоцентрового исследования чувстви- тельности стафилококков к антибиотикам в Москве и Санкт-Петербурге. Антибиот. Химиотер. 1998, v. 43, p. 15-25.

Copyright © Pharmarus Print Media, 2008



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies